The aspirin heart disease prevention conundrum

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacogenomics

Background:

• Daily aspirin use for primary prevention of cardiovascular disease (CVD) presents a dilemma due to balanced risks of CVD event reduction and gastrointestinal (GI) bleeding.
• Lipoprotein (a) [LPA] is a key risk factor for atherosclerotic cardiovascular disease.
• Genetic variations in LPA may influence individual responses to aspirin therapy.

Purpose of the Study:

• To investigate the role of LPA polymorphisms in identifying patients who benefit from primary aspirin prophylaxis.
• To determine if LPA variant carriers experience differential cardiovascular event reduction with aspirin compared to non-carriers.

Main Methods:

• Analysis of clinical trial data focusing on the LPA variant rs3798220.
• Comparison of coronary heart disease (CHD) event rates in carriers and non-carriers of the LPA variant, with and without aspirin treatment.

Main Results:

• Carriers of the LPA variant (rs3798220) exhibit a higher risk of CHD events compared to non-carriers.
• Aspirin treatment significantly reduced major CHD events in LPA variant carriers to levels comparable to non-carriers.
• The cardiovascular benefits of aspirin in carriers outweigh the increased risk of serious GI bleeding.

Conclusions:

• Genetic testing for LPA variants can personalize aspirin therapy for primary CVD prevention.
• Identifying LPA variant carriers allows for targeted aspirin use, maximizing cardiovascular risk reduction.
• This approach offers an inexpensive strategy to optimize primary prevention for specific patient populations.